Connecting Cancer Genes - Study Implicates 350 Gene Regions In Cancer Development In The Mouse, UK

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: 16 May 2008 - 1:00 PDT


A large genetic study in mice has identified hundreds of genes involved in the development of cancer by examining the DNA of more than 500 lymphomas to find the cancer causing mutations.

The study found just over 10,000 mutations in total, which together implicate almost 350 regions in the mouse genome in cancer formation. 50 of these regions correspond to genes known to be involved in human cancers while the other regions were novel, adding to our picture of the complex set of diseases that are cancers.

The results were obtained by an international consortium of researchers, led by Drs Anton Berns, Maarten van Lohuizen and Lodewyk Wessels from the Netherlands Cancer Institute (NKI), and Dr David Adams, Experimental Cancer Genetics, from the Wellcome Trust Sanger Institute and are published in Cell.

The team used a virus called the murine leukaemia virus to produce mutations in cancer genes: the virus targets white blood cells, resulting in lymphoma, a common tumour of the blood system.

"Human cancers are generally thought to be formed by the stepwise accumulation of mutations that disrupt genes within a cell, and the virus mimics this process as it inserts itself into the mouse genome," explains Dr David Adams, senior author on the paper. "The virus then acts as a 'tag', allowing us to identify where it has integrated and which gene or genes have been disrupted.

"By finding an average of 20 mutations from each of the 500 tumours, not only did we find many new cancer genes, but we can see which genes work together in the same cell to transform it into a lymphoma," says Dr Jaap Kool, co-first author on the paper from the NKI.

The infected mouse lines carried mutations in genes called p53 and p19, which are known to suppress the development of cancer and are among the most commonly mutated genes in human cancers. The team were able to identify a rich set of novel genes implicated in cancer, including additional genes that might act to suppress tumour development, which are not readily detected in most surveys.

Human cancer cells frequently contain many mutations that are not involved in the development of cancer - do not drive cancer development - but are produced by increased mutation rates in cancer cells and are 'passengers'. Discerning which are driver and which are passenger mutations is a challenge for human cancer gene studies.

"The benefit of our system in the mouse is that, unlike human tumours, which usually contain many different types of genetic alternations, the causal mutations that initiate these tumours in mice can be easily identified and studied," explains Dr Adams, "These studies are complementary to and enrich the analysis of human cancers."

The project was made possible by the Sanger Institute's high-throughput sequencing and computational resources, which allowed the team to identify new potential cancer genes in the mouse. By comparing their data to genome-wide human cancer datasets generated by the Sanger Institutes' Cancer Genome Project, they could show that at some of the newly identified genes were potentially relevant to human cancer formation.

The team are currently carrying out other cancer screens using viruses and additional methods to disrupt cancer genes. These screens are searching for genes and gene interactions in the formation of bowel, lymphoid and breast cancers.

Notes:

Publication details

Large scale mutagenesis in p19ARF- and p53-deficient mice identifies cancer genes and their collaborative networks.
Uren AG et al. (2008)
Cell, published online Friday 16 May 2008
doi: http://dx.doi.org/10.1016/j.cell.2008.03.021

Participating Institutions

- Division of Molecular Genetics and Cancer Genomics Centre, Division of Molecular Biology and Central Microarray Facility, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands

- Information and Communication Theory Group, Faculty of Electrical Engineering, Mathematics, and Computer Science, Delft University of Technology, Delft, The Netherlands

- Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, UK

Funding

This research was funded by the Netherlands Organisation for Scientific Research (NWO) Genomics and the Cancer Genomics Centre, the BioRange program of the Netherlands Bioinformatics Centre (NBIC), which is supported by a BSIK grant through the Netherlands Genomics Initiative (NGI), a Horizon Breakthrough Project grant from the NGI, the Wellcome Trust Sanger Institute sequencing facility, Cancer Research-UK and the Wellcome Trust.

The Netherlands Cancer Institute (NKI) The Netherlands Cancer

Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) accommodates approximately 550 scientists and scientific support personnel, and 53 medical specialists. The hospital has an out-patients clinic that receives 24,000 new patients each year and has 180 beds, 5 operating theaters and 9 irradiation units. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training. The NKI-AVL studies all major areas of cancer research, with special emphasis on cell-based screens, mouse tumor models, cell biology, structural biology and epidemiology.

Delft University of Technology, Founded in 1842, Delft University of Technology is the oldest, largest, and most comprehensive technical university in the Netherlands. With over 13,000 students and 2,100 scientists (including 200 professors), it is an establishment of both national importance and significant international standing.

Renowned for its high standard of education and research, TU Delft collaborates with other educational establishments and research institutes, both within and outside of the Netherlands. It also enjoys partnerships with governments, trade organizations, numerous consultancies, industry and small and medium sized enterprises.

The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992 as the focus for UK sequencing efforts. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms such as mouse and zebrafish, and more than 90 pathogen genomes. In October 2005, new funding was awarded by the Wellcome Trust to enable the Institute to build on its world-class scientific achievements and exploit the wealth of genome data now available to answer important questions about health and disease. These programmes are built around a Faculty of more than 30 senior researchers. The Wellcome Trust Sanger Institute is based in Hinxton, Cambridge, UK.

http://www.sanger.ac.uk

The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending around £650 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing.

The Wellcome Trust

• Additional
• References
• Citations